Shields Matthew sold $532K of TEVA

Teva Pharmaceuticals announced FDA approval of Weltruza, a once-monthly subcutaneous olanzapine injection for schizophrenia. The drug, available in three strengths, does not require post-injection monitoring. Teva expects U.S. availability soon. The SOLARIS trial showed improved symptoms and tolerability. Weltruza's list price is $3,950. (280 characters)

Teva Pharmaceutical (TEVA) reported a 2% revenue decline in Q3 2026, driven by a 16% drop in generics revenue. The company discontinued a Phase II study and faces challenges with AUSTEDO revenue due to pricing pressures. CEO Richard Francis and CFO Eli Kalif discussed gross margin expansion, IRA impact, and growth drivers like UZEDY, AJOVY, and WELTRUZA. Teva expects AUSTEDO to reach $2.5B in 2027 and over $3B at peak, despite litigation risks and biosimilar challenges.

The FDA approved Teva Pharmaceuticals USA's generic fluticasone propionate inhaler in 0.11 mg and 0.22 mg strengths, rated AB for therapeutic equivalence to Flovent HFA. The approval, under ANDA 209917, is a regulatory milestone but lacks financial impact data.

H.C. Wainwright raised Teva's (NYSE:TEVA) price target to $54 from $52, citing strong Q3 results. Revenue was $4.395B (down 2% YoY, up 6% sequentially), and EPS was $0.86 (beating estimates). The company raised its full-year revenue guidance to $16.7B-$17.0B. Austedo, Ajovy, and Uzedy drove higher expectations. BofA Securities also raised its target to $48.

Teva Pharmaceutical Industries (TEVA) reported Q3 non-GAAP gross margin of 58.7%, up 2.45% from last year. Free cash flow was $495M. The company raised full-year revenue guidance to $16.7B-$17B. Teva expects flat generics revenue in 2026, excluding generic REVLIMID, and anticipates biosimilar sales to hit $800M, a year ahead of schedule.

Teva and Samsung Bioepis agreed to a $420M deal for two biosimilars. Teva gains US rights to RENFLEXIS (infliximab-abda), which can be sold immediately, and ETICOVO (etanercept-ykro), blocked from US sales until 2029 due to patent disputes. The deal includes upfront, launch, and sales milestones. Teva aims to leverage its distribution network to boost RENFLEXIS's market share, while ETICOVO's launch is delayed by legal restrictions.